Find clinical trials for Multiple Myeloma in Pittsburgh, PA
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Multiple Myeloma trials near Pittsburgh, PA, USA:
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Pittsburgh, Pennsylvania, United States and 59 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Pittsburgh, Pennsylvania, United States and 126 other locations
of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and ...
Phase 1
Monroeville, Pennsylvania, United States and 21 other locations
and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple...
Phase 1
Pittsburgh, Pennsylvania, United States and 18 other locations
A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...
Phase 3
Pittsburgh, Pennsylvania, United States and 180 other locations
Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...
Phase 3
Pittsburgh, Pennsylvania, United States and 135 other locations
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to ide...
Phase 1
Pittsburgh, Pennsylvania, United States and 26 other locations
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to id...
Phase 1
Pittsburgh, Pennsylvania, United States and 30 other locations
maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple...
Phase 3
Pittsburgh, Pennsylvania, United States and 270 other locations
The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Phase 2
Pittsburgh, Pennsylvania, United States and 46 other locations
Clinical trials
Research sites
Resources
Legal